Conceptos Categóricos

Crónicas de autores

Flávio Reis *

Autor invitado por SIIC


A PLAQUETA COMO MARCADOR PRECOCE DE RISCO CARDIOVASCULAR NA DEFICIÊNCIA DE HORMONA DE CRESCIMENTO

Nos doentes com deficiência de hormona de crescimento (DHC) com início na infância e que mantêm a deficiência após supressão da terapêutica com HC, mas não nos que recuperam os níveis normais, verifica-se uma hiperactivação plaquetar na ausência de outros indicadores de risco cardiovascular, podendo constituir um marcador precoce e eventualmente recomendar terapia anti-agregante preventiva.

*Flávio Reis
describe para SIIC los aspectos relevantes de su trabajo
PLATELET HYPERACTIVATION IN MAINTAINED GROWTH HORMONE-DEFICIENT CHILDHOOD PATIENTS AFTER THERAPY WITHDRAWAL AS A PUTATIVE EARLIER MARKER OF INCREASED CARDIOVASCULAR RISK
Journal of Clinical Endocrinology and Metabolism,
90(1):98-105 Ene, 2005

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Unit of Therapeutics, Institute of Pharmacology and Experimental Therapeutics, Medicina Faculty, Coimbra, Portugal, Coimbra, Portugal
Imprimir nota
Referencias bibliográficas
1. Rosén T, Bengtsson BA. 1990 Premature mortality due to cardiovascular diseases in hypopituitarism. Lancet 336:285-288.
2. Besson A, Salemi S, Gallati S, Jenal A, Horn R, Mullis PS, Mullis PE 2003 Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab 88:3664-3667.
3. Colao A, Di Somma C, Pivonello R, Cuocolo A, Spinelli L, Bonaduce D, Salvatore M, Lombardi G 2002 The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metab 87:1088-1093.
4. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM 1997 Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 46:75-81.
5. Carrol PV, Christ ER, Bengtsson B-A, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T, Thorner M 1998 Growth hormone deficiency in adulthood and effect of growth hormone replacement: a review. J Clin Endocrinol Metab 83:382-395.
6. Colao A, Di Somma C, Salerno M, Spinelli L, Orio F, Lombardi G 2002 The cardiovascular risk of adult GH deficiency adolescents. J Clin Endocrinol Metab 87:3650-3655.
7. Sas T, Mulder P, Hokken-Koelega A 2000 Body composition, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab 85:3786-3792.
8. Whitehead HM, Boreham C, McIlrath EM, Sheridan B, Kennedy L, Atkinson AB, Hadden DR 1992 Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol 36:45-52.
9. Florkowski CM, Collier GR, Zimmet PZ, Livesey JH, Espiner EA, Donald RA 1996 Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. Clin Endocrinol 45:769-773.
10. Vahl N, Jorgensen JOL, Hansen TB, Klausen IB, Jurik A-G, Hagen C, Christiansen JS 1998 The favourable effects of growth hormone (GH) substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12-month placebo-controlled study. Int J Obesity 22:529-536.
Otros artículos de Flávio Reis

Reis F, Ponte L, Rocha L, Almeida L, Alcobia T, Lourenço M, Palmeiro A, Ferrer-Aantunes CA, Costa-Almeida C, Teixeira F. Curative isosorbide-5-mononitrate treatment, in opposition to the beneficial preventive one, aggravates the prothrombotic and proconstrictor state in cyclosporin-induced hypertensive rats. Clin Exp Pharmacol Physiol 2005; (in press).

Reis F, Rocha L, Ponte L, Alcobia T, Almeida L, Costa-Almeida C, Teixeira F. Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. Life Sciences 2005; (in press).

HM Teixeira, Reis F, Quintela O, López-Rivadulla M, Proença P, Angelines C, Pipo P, Marques E, Vieira DN. Vitreous humor as a complementary sample to blood for the detection/confirmation of diazepam: ante-mortem and post-mortem studies in an animal model. Human & Exp Toxicol 2004; 23(12):571-577.

Santiago M, Reis F, Almeida L, Alcobia T, Dionísio J, Teixeira F. Impairment of vascular and platelet nitric oxide and 3',5' cyclic guanosine monophosphate content in cyclosporin A-induced hypertensive rats. Fund Clin Pharmacol 2003; 17:43-50.

Reis F, Almeida L, Alcobia T, Santos-Dias JD, Lourenço M, Palmeiro A, Ferrer-Antunes CA, Mesquita JF, Pontes F, Teixeira F. Isosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide-cyclic guanosine-3’,5’-monophosphate disturbances. Thromb Res 2003; 110:107-115.

Reis F, Hermida RC, Souza I, Maldonado J, Tavares P, Fontes-Ribeiro CA, Teixeira HM, Alcobia T, Almeida L, Teixeira F. Circadian and seasonal variations of endogenous ubiquinone plasma levels. Chronobiol Int 2002; 19(3):599-614.

Tavares P, Reis F, Fontes-Ribeiro CA, Teixeira F. Cardiovascular effects of cyclosporine A in an experimental model. Rev Port Cardiol 2002; 21(2):141-155.

Reis F, Tavares P, Rito LC, Teixeira HM, Santos-Dias JD, Ferrer-Antunes C, Mesquita JF, Teixeira F. Platelet activation is increased in cyclosporin A-induced hypertensive rats. J Cardiovasc Pharmacol 2000; 36(1):56-64.

Reis F, Tavares P, Teixeira F. The distribution of catecholamines between plasma and platelets in cyclosporin A-induced hypertensive rats. Pharmacol Res 2000; 41(2):129-135.

Reis F, Tavares P, Fontes Ribeiro CA, Ferrer Antunes CA, Teixeira F. The peripheral serotonergic system and platelet aggregation in cyclosporin A-induced hypertensive rats. Thromb Res 1999; 96:365-372.

Para comunicarse con Flávio Reis mencionar a SIIC como referencia:
flavio@ci.uc.pt

Autor invitado
8 de abril, 2005
Descripción aprobada
22 de julio, 2005
Reedición siicsalud
18 de noviembre, 2021

Acerca del trabajo completo
A PLAQUETA COMO MARCADOR PRECOCE DE RISCO CARDIOVASCULAR NA DEFICIÊNCIA DE HORMONA DE CRESCIMENTO

Título original en castellano
A HIPERACTIVAÇÃO PLAQUETAR COMO UM POSSIVEL MARCADOR PRECOCE DE RISCO CARDIOVASCULAR AUMENTADO EM DOENTES COM DEFICIÊNCIA DE HORMONA DE CRESCIMENTO EM CRIANÇA MANTIDA APOS A SUPRESSÃO DA TERAPÊUTICA

Autor


Acceso a la fuente original
Journal of Clinical Endocrinology and Metabolism
http://jcem.endojournals.org
Acceso al texto original completo (full text)
http://jcem.endojournals.org/cgi/content/full/90/1/98
Acceso al resumen/abstract original
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15494463&dopt=Abstract
El artículo se relaciona estrictamente con las especialidades de siicsalud


ua40317
-->